NovaBay Pharmaceuticals Inc (NBY) has a current Price-to-Book (P/B) ratio of -13.15. Compared to its 3-year average P/B ratio of -0.62, the current P/B ratio is approximately 2024.49% higher. Relative to its 5-year average P/B ratio of 0.31, the current P/B ratio is about -4321.31% higher. NovaBay Pharmaceuticals Inc (NBY) has a Forward Free Cash Flow (FCF) yield of approximately 0.40%. Compared to its 3-year average FCF yield of -142.79%, the current FCF yield is approximately -100.28% lower. Relative to its 5-year average FCF yield of -115.64%, the current FCF yield is about -100.35% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for NBY competitors is 11.05, providing a benchmark for relative valuation. NovaBay Pharmaceuticals Inc Corp (NBY.A) exhibits a P/S ratio of 61.64, which is 458.08% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of NBY increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of NBY in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is NBY currently overvalued or undervalued?

What is NovaBay Pharmaceuticals Inc (NBY) fair value?

NBY's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of NovaBay Pharmaceuticals Inc (NBY) is between to according to relative valuation method.

How does NBY's valuation metrics compare to the industry average?

The average P/S ratio for NBY's competitors is 11.05, providing a benchmark for relative valuation. NovaBay Pharmaceuticals Inc Corp (NBY) exhibits a P/S ratio of 61.64, which is 458.08% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

What is the current P/B ratio for NovaBay Pharmaceuticals Inc (NBY) as of Mar 02 2026?

As of Mar 02 2026, NovaBay Pharmaceuticals Inc (NBY) has a P/B ratio of -13.15. This indicates that the market values NBY at -13.15 times its book value.

What is the current FCF Yield for NovaBay Pharmaceuticals Inc (NBY) as of Mar 02 2026?

As of Mar 02 2026, NovaBay Pharmaceuticals Inc (NBY) has a FCF Yield of 0.40%. This means that for every dollar of NovaBay Pharmaceuticals Inc's market capitalization, the company generates 0.40 cents in free cash flow.

What is the current Forward P/E ratio for NovaBay Pharmaceuticals Inc (NBY) as of Mar 02 2026?

As of Mar 02 2026, NovaBay Pharmaceuticals Inc (NBY) has a Forward P/E ratio of -6.83. This means the market is willing to pay $-6.83 for every dollar of NovaBay Pharmaceuticals Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for NovaBay Pharmaceuticals Inc (NBY) as of Mar 02 2026?

As of Mar 02 2026, NovaBay Pharmaceuticals Inc (NBY) has a Forward P/S ratio of 61.64. This means the market is valuing NBY at $61.64 for every dollar of expected revenue over the next 12 months.

NBY Valuation